StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Enbrel (etanercept by Year

Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) ($M)

Pfizer Enbrel (etanercept: $627M in FY2025, down 9.1% from a year earlier.

Latest, FY2025
627
Period ended Dec 31, 2025
Change on a year earlier
-9.1%
690 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Enbrel (Outside the U.S. and Canada) | 627 | 690 | (9%) | (9%) | — | — | — | 627 | 690 | (9%) | (9%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up enbrel (etanercept

Cite this data

StockData. (2026). Pfizer Enbrel (etanercept ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/enbrel-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.